Heska Corporation (NASDAQ:HSKA) insider Michael J. Mcginley sold 7,826 shares of the stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total value of $681,957.64. Following the sale, the insider now owns 106,771 shares in the company, valued at approximately $9,304,024.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Heska Corporation (NASDAQ:HSKA) traded up $0.49 during midday trading on Friday, hitting $86.32. The stock had a trading volume of 70,273 shares, compared to its average volume of 70,037. The firm has a market capitalization of $623.72, a price-to-earnings ratio of 44.94, a P/E/G ratio of 2.29 and a beta of 0.83. Heska Corporation has a 52 week low of $64.52 and a 52 week high of $115.00.

Heska (NASDAQ:HSKA) last announced its earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.03. Heska had a return on equity of 15.35% and a net margin of 10.67%. The business had revenue of $31.40 million for the quarter, compared to analyst estimates of $36.10 million. During the same quarter last year, the firm earned $0.45 EPS. Heska’s revenue for the quarter was down 6.0% compared to the same quarter last year. sell-side analysts expect that Heska Corporation will post 2.03 EPS for the current fiscal year.

Several equities analysts recently issued reports on the company. B. Riley decreased their price target on Heska from $96.50 to $93.00 and set a “neutral” rating on the stock in a report on Friday, November 3rd. Canaccord Genuity assumed coverage on Heska in a report on Thursday, October 5th. They issued a “buy” rating and a $115.00 price target on the stock. Zacks Investment Research cut Heska from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. BidaskClub cut Heska from a “buy” rating to a “hold” rating in a report on Monday, August 14th. Finally, Benchmark reissued a “buy” rating and issued a $120.00 target price (up previously from $106.00) on shares of Heska in a research note on Wednesday, August 9th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $113.30.

A number of institutional investors have recently made changes to their positions in the stock. Teachers Advisors LLC grew its stake in Heska by 11.6% in the first quarter. Teachers Advisors LLC now owns 10,590 shares of the medical research company’s stock valued at $1,112,000 after purchasing an additional 1,097 shares in the last quarter. California Public Employees Retirement System grew its stake in Heska by 38.1% in the first quarter. California Public Employees Retirement System now owns 10,880 shares of the medical research company’s stock valued at $1,142,000 after purchasing an additional 3,000 shares in the last quarter. Vanguard Group Inc. grew its stake in Heska by 47.0% in the first quarter. Vanguard Group Inc. now owns 350,609 shares of the medical research company’s stock valued at $36,807,000 after purchasing an additional 112,115 shares in the last quarter. Geode Capital Management LLC grew its stake in Heska by 9.3% in the first quarter. Geode Capital Management LLC now owns 54,081 shares of the medical research company’s stock valued at $5,677,000 after purchasing an additional 4,623 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in Heska in the first quarter valued at approximately $5,853,000. 81.98% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Insider Selling: Heska Corporation (HSKA) Insider Sells $681,957.64 in Stock” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/02/insider-selling-heska-corporation-hska-insider-sells-681957-64-in-stock.html.

About Heska

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Insider Buying and Selling by Quarter for Heska (NASDAQ:HSKA)

Receive News & Stock Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related stocks with our FREE daily email newsletter.